RE DeGryse

2.0k total citations · 2 hit papers
10 papers, 1.4k citations indexed

About

RE DeGryse is a scholar working on Psychiatry and Mental health, Neurology and Pathology and Forensic Medicine. According to data from OpenAlex, RE DeGryse has authored 10 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Psychiatry and Mental health, 6 papers in Neurology and 5 papers in Pathology and Forensic Medicine. Recurrent topics in RE DeGryse's work include Migraine and Headache Studies (9 papers), Botulinum Toxin and Related Neurological Disorders (6 papers) and Ophthalmology and Eye Disorders (3 papers). RE DeGryse is often cited by papers focused on Migraine and Headache Studies (9 papers), Botulinum Toxin and Related Neurological Disorders (6 papers) and Ophthalmology and Eye Disorders (3 papers). RE DeGryse collaborates with scholars based in United States, Germany and Ireland. RE DeGryse's co-authors include DW Dodick, CC Turkel, HC Diener, SK Aurora, RB Lipton, SD Silberstein, Isaac Willis, Richard B. Lipton and HC Diener and has published in prestigious journals such as Cephalalgia, The Journal of Headache and Pain and Clinical Drug Investigation.

In The Last Decade

RE DeGryse

10 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial

2010 744 citations SK Aurora, DW Dodick et al. Cephalalgia profile →
OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial

2010 676 citations HC Diener, DW Dodick et al. Cephalalgia profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
RE DeGryse United States	4	1.3k	962	745	513	130	10	1.4k
CC Turkel United States	6	1.8k 1.4×	1.3k 1.4×	995 1.3×	632 1.2×	211 1.6×	14	2.0k
Giorgio Lambru United Kingdom	23	1.3k 1.0×	967 1.0×	511 0.7×	264 0.5×	103 0.8×	80	1.6k
AN Manack United States	5	1.6k 1.2×	1.0k 1.1×	553 0.7×	189 0.4×	172 1.3×	12	1.7k
G Zanchin Italy	19	868 0.7×	551 0.6×	337 0.5×	137 0.3×	107 0.8×	63	1.1k
Arthur H. Elkind United States	17	678 0.5×	450 0.5×	438 0.6×	149 0.3×	118 0.9×	27	861
G. C. Manzoni Italy	20	1.2k 0.9×	785 0.8×	545 0.7×	89 0.2×	105 0.8×	60	1.3k
AM Rapoport United States	16	819 0.6×	547 0.6×	359 0.5×	155 0.3×	115 0.9×	23	985
R. Michael Gallagher United States	15	734 0.6×	466 0.5×	324 0.4×	94 0.2×	114 0.9×	27	858
Yngve Hallström United States	8	807 0.6×	492 0.5×	265 0.4×	137 0.3×	65 0.5×	11	964
Ferdinando Maggioni Italy	17	713 0.6×	411 0.4×	210 0.3×	140 0.3×	79 0.6×	82	903

Countries citing papers authored by RE DeGryse

Since Specialization

Citations

This map shows the geographic impact of RE DeGryse's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by RE DeGryse with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites RE DeGryse more than expected).

Fields of papers citing papers by RE DeGryse

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by RE DeGryse. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by RE DeGryse. The network helps show where RE DeGryse may publish in the future.

Co-authorship network of co-authors of RE DeGryse

This figure shows the co-authorship network connecting the top 25 collaborators of RE DeGryse. A scholar is included among the top collaborators of RE DeGryse based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with RE DeGryse. RE DeGryse is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

1.

Diener, HC, DW Dodick, RE DeGryse, & CC Turkel. (2013). OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients without medication overuse. The Journal of Headache and Pain. 14(S1). 3 indexed citations

2.

Diener, HC, DW Dodick, RE DeGryse, & CC Turkel. (2013). OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients without medication overuse. The Journal of Headache and Pain. 14(Suppl 1). P204–P204. 1 indexed citations

3.

Dodick, DW, RE DeGryse, & CC Turkel. (2013). Headache symptoms of the PREEMPT population. The Journal of Headache and Pain. 1(Suppl 1). P99–P99. 1 indexed citations

4.

Aurora, SK, DW Dodick, RE DeGryse, & CC Turkel. (2013). OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all 5 treatment cycles in PREEMPT. The Journal of Headache and Pain. 1(Suppl 1). P199–P199. 1 indexed citations

5.

Silberstein, SD, DW Dodick, RE DeGryse, Richard B. Lipton, & CC Turkel. (2013). The percent of chronic migraine patients who responded to onabotulinumtoxinA treatment per treatment cycle in the PREEMPT clinical program. The Journal of Headache and Pain. 14(S1). 4 indexed citations

6.

Aurora, SK, DW Dodick, RE DeGryse, & CC Turkel. (2013). OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all 5 treatment cycles in PREEMPT. The Journal of Headache and Pain. 14(S1). 1 indexed citations

7.

Dodick, DW, RE DeGryse, & CC Turkel. (2013). Headache symptoms of the PREEMPT population. The Journal of Headache and Pain. 14(S1). 1 indexed citations

8.

Diener, HC, DW Dodick, SK Aurora, et al.. (2010). OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 30(7). 804–814. 676 indexed citations breakdown →

9.

Aurora, SK, DW Dodick, CC Turkel, et al.. (2010). OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 30(7). 793–803. 744 indexed citations breakdown →

10.

Willis, Isaac, et al.. (1991). Naftifine 1% Cream in the Treatment of Tinea Cruris and Tinea Corporis. Clinical Drug Investigation. 3(1). 57–59. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact